Score one for GlaxoSmithKline. The company won an injunction against the U.S. Patent and Trademark Office, successfully blocking implementation of new rules governing patent continuances, at least temporarily.
GSK will now ask the court to permanently scrap the rules, which were set to go into effect today. The rules would have reduced the number of times a patent holder could dicker with rejected or pending patent, and GSK claimed they would hamstring innovation.
GSK sues over new patent rules. Report
Standards on biotech patents get tougher. Report
Behind the scenes of GSK's overhaul. Report
GSK plant closure begins 5,000 job cuts. Report
Glaxo to cut $1.4B on falling sales. Report